Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Biochem ; 143(3): 311-24, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18024965

ABSTRACT

We previously showed that tandem-repeat type galectin-8, which has two covalently linked carbohydrate recognition domains (CRDs), induces neutrophil-adhesion through binding to integrin alphaM. Here, we analysed the function of galectin-8 in Jurkat T-cells. Galectin-8, as well as tandem-repeat galectin-9, and several multivalent plant lectins, induced Jurkat T-cell adhesion to a culture plate, whereas single-CRD galectins-1 and -3 did not. Galectin-8 also induced the adhesion of peripheral blood leucocytes to human umbilical vein endothelial cells. These results suggest that the di- or multi-valent structure of galectin-8 is essential for the induction of cell adhesion and that this ability exhibits broad specificity for leucocytes. The galectin-8-induced cell adhesion was accompanied by stress fibre formation, which suggests that intracellular signalling is required. We have identified integrin alpha4 as one of the candidate target molecules associated with the induction of cell adhesion. Indeed, inhibition of the function of integrin alpha4 by treating cells with a blocking-antibody reduced the sensitivity to galectin-8. Also, the phosphorylation of Pyk and ERK1/2, indicators of integrin-mediated signalling, was up-regulated on treatment with galectin-8. Thus, a primary target of galectin-8 must be the sugar chains on members of the integrin family, which are abundantly expressed on the surface of leucocytic cells.


Subject(s)
Galectins/metabolism , T-Lymphocytes/cytology , T-Lymphocytes/metabolism , Actins/metabolism , Carbohydrate Metabolism/drug effects , Cell Adhesion/drug effects , Concanavalin A/pharmacology , Cytoskeleton/drug effects , Cytoskeleton/metabolism , Endothelial Cells/cytology , Endothelial Cells/drug effects , Endothelial Cells/metabolism , Enzyme Activation/drug effects , Extracellular Signal-Regulated MAP Kinases/metabolism , Fluorescent Antibody Technique , Glycoproteins/metabolism , Humans , Integrins/metabolism , Jurkat Cells , Leukocytes/cytology , Leukocytes/drug effects , Leukocytes/metabolism , Membrane Proteins/metabolism , Plant Lectins/metabolism , Protein Transport/drug effects , RNA, Small Interfering/metabolism , Signal Transduction/drug effects , T-Lymphocytes/drug effects , T-Lymphocytes/enzymology
2.
J Biochem ; 141(2): 157-72, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17167046

ABSTRACT

Galectin-9, a mammalian lectin with affinity for beta-galactosides, is known as an apoptosis inducer of activated T lymphocytes. In the present study, we examined the properties of galectin-9-mediated cell death of Jurkat T cells. Galectin-9NC (wild-type), consisting of two CRDs (N-terminal and C-terminal carbohydrate recognition domains), and derivatives of it, galectins-9-NN and -9-CC, induced Jurkat T-cell apoptosis. However, a single CRD (galectin-9NT or -CT) had no effect, suggesting the stable dimeric structure of two CRDs is required for the activity. The apoptosis was inhibited by pretreatment with an N-glycan synthesis inhibitor, indicating that the expression of N-glycans in the cells is essential for galectin-9-induced apoptosis. We previously showed that the apoptosis of MOLT-4 cell is mediated by galectin-9 via a Ca(2+)-calpain-caspase-1-dependent pathway. In Jurkat cells, the cell death by galectin-9, was insufficiently suppressed by caspase inhibitors, Ca(2+)-chelator or calpain inhibitor. Furthermore, we observed the loss of mitochondrial membrane potential and significant AIF release in galectin-9-treated cells. These findings suggest that caspase-dependent and-independent death pathways exist in Jurkat cells, and the main pathway might vary with the T-cell type.


Subject(s)
Apoptosis , Galectins/metabolism , T-Lymphocytes/cytology , Apoptosis/drug effects , Calcium/metabolism , Caspase 1/metabolism , Cell Line, Tumor , Cysteine Proteinase Inhibitors/pharmacology , Humans , Jurkat Cells , Recombinant Proteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL